Arrivent Biopharma received FDA IND clearance for ARR-217, a CDH-17 targeted ADC

CAR-T Digest - August 2020

10 November 2025: Arrivent Biopharma received FDA IND clearance for ARR-217, a CDH-17 targeted ADC

ArriVent highlighted steady progress across its pipeline, including FDA IND clearance for ARR-217, a CDH17-targeted ADC now advancing through an ongoing Phase 1 study in gastrointestinal cancers
The company emphasized ARR-217 as a lead ADC candidate with best-in-class potential, supported by continued dose escalation work in partnership with Lepu Biopharma
Alongside the IND milestone, ArriVent showcased strong momentum in its broader ADC portfolio, noting plans to bring additional ADC programs toward the clinic
These achievements were presented as part of a broader update on corporate and clinical progress, backed by a solid financial position with over $305 million in cash supporting operations into mid-2027
ArriVent framed the IND clearance for ARR-217 as a key step in delivering multiple near-term catalysts, reinforcing its strategy to expand innovative therapies across major solid tumor indications